ClinicalTrials.gg
Status unknownNCT03480399LTMUpdated Aug 7, 2019

Long Term Morbidity and Quality of Life in Retroperitoneal Sarcomas

An observational study in Sarcoma, Soft Tissue, Retroperitoneal Neoplasms and Surgery, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-07.

Sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Observational

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

No prospective data exist about long term morbidity and quality of life after multivisceral surgical resection for retroperitoneal soft tissue sarcoma (RSTS).

In order to assess the safety of this surgical approach and the effect on the Quality of Life over the long period we propose a prospective observational study.

The hypothesis is that the surgical treatment has no significant impact in determining a lower Quality of Life in the long term.

Objectives Primary objective Estimate the difference between baseline and 4 and 12 months scores of the "global health status / QoL" scale in patients primarily treated for localized RSTS, as determined in QLQ-C30 version 3.0.

Secondary objectives

  • Evaluate the long term morbidity of aggressive surgical approach to RSTS in terms of renal failure.
  • Evaluate the difference between baseline and 4 and 12 months scores of DN4 / LEFS / BPI questionnaires.
  • Evaluate the difference between baseline and 4 and 12 months scores of the following scales from QLC-C30: PF2, RF2, EF, CF, SF, FA, FI.
  • Evaluate the difference between baseline and 4 and 12 months scores of the following scales and single items from QLC-C29: Blood and mucus in stool, Stool frequency, Sexual interest, Impotence, Dyspareunia.
  • To correlate the surgical resection pattern (number and type of organs resected) and the tumor features (size, grading and histological subtype) with the long-term morbidity and quality of life.

Eligibility Inclusion criteria

  • Adult patients (age > 18 years) with primary localized RSTS surgically treated at our institution
  • Written, voluntary, informed consent

Exclusion criteria

  • Recurrent disease
Read the detailed description

Study description This is an observational study aimed to prospectively evaluate the long term morbidity of aggressive surgical approach to RSTS and the impact over the patients' quality of life. Consecutive patients candidate to surgery for primary RSTS will be offered to be enrolled. We plan to include all the RSTS patients consecutively operated on for primary retroperitoneal sarcoma from first accrual on up to the 24 months after the study start.

At the entrance of the study, an informed written consent will be obtained. Study participants will be asked to complete four self-filled in one-off questionnaires (see "Study parameters" paragraph).

Study parameters Study parameters EORTC QLQ-CR29 and EORTC QLQ C30 questionnaires (baseline, 4 mos, 12 mos) LEFS questionnaire (baseline, 4 mos, 12 mos) BPI questionnaire (baseline, 4 mos, 12 mos) DN4 questionnaire (baseline, 4 mos, 12 mos) Serum creatinin (baseline, 4 mos, 12 mos) Morbidity events (4 mos, 12 mos) Neurologic exam of lower limbs (baseline, 4 mos, 12 mos) Disease status (4 mos, 12 mos)

* In case of preoperatory complementary treatment, the questionnaires will be administrated just before the beginning of the treatment.

  • Quality of Life: the core questionnaire, the EORTC QLQC30,is an extensively validated questionnaire for the assessment of health related quality of life in cancer patients (Aaronson 1991). It contains both functional (physical, role, cognitive, emotional, social), and physical symptom multidimensional scales (fatigue, pain, and nausea and vomiting) as well as two single item "global health status" and "quality of life" scales, plus several single-item symptom measures. The QLQ-CR29 is a condition specific module (colo-rectal disease) developed to be used in conjunction with EORTC QLQC30; it is made up of 29 items for a total of four scales assessing urinary frequency, faecal seepage, stool consistency and body image as well a number single items scales. Both the tools are available and validated in the Italian language.
  • Femoral Impairment: the dedicated questionnaire (Lower Extremity Functional Scale - Italian Version, LEFS questionnaire) will investigated daily life activities that require ad adequate function of knee joint stability and quadriceps strength as a surrogate of motor impairment of homolateral femoral nerve.
  • Chronic Pain Syndrome: the Italian version of the 'Brief Pain Inventory Short form" (BPI, attached) ( ) will be administered in order to obtain information on pain status at censored time (basal, 4 and 12 months after surgery values).
  • Neuropathic Pain: the Italian version of "Douleur Neuropathique en 4 Questions" (DN4, attached) will be administered in order to obtain information on neuropathic pain at censored time (basal, 4 and 12 months after surgery scores).
  • Long term morbidity: morbidity events will specifically regard femoral nerve impairment at physical examination, abdominal complications, sexual life and physiological functions. Renal failure in particular will be investigated by renal function blood tests monitoring and glomerular filtration rate (GFR) calculated according to Cockroft-Gault and simplified MDRD (Modification of Diet in Renal Disease) methods. Serum creatinine value will also be registered. Renal failure will be defined according to National Kidney Foundation 2002 criteria (Stage 2 or higher), and classified according to GFR thresholds.
  • Disease status will be recorded and in case of local and/or distant relapse the date of events will also be retrieved.

Statistical considerations Statistical analyses

  1. Primary end-point The two-sided 95% confidence interval (95%CI) of the paired difference between baseline and 4 (or12) months scores will be calculated for the primary outcome scale variables (items "29" and "30" QLQ-C30).
  2. Secondary end-points Descriptive statistics and frequency tabulation were used to summarize patient characteristics and long term morbidity profile. Continuous variables will be described with appropriate summary statistics such as the mean, median, standard deviation, minimum and maximum. Categorical variables will be tabulated with frequencies and percentages. The probabilities of renal failure and femoral neuropathy will be estimated by the corresponding relative frequencies; their corresponding 95% confidence limits will be calculated using the exact method, i.e. taking into account the binomial distribution of proportions. The binary associations between the surgical resection pattern (number and type of organs resected) and the tumor features (size, grading and histological subtype) will be tested by using exact chi-square test. As regards the quantitative parameters measured over time, summary statistics (mean, median, standard deviation, minimum and maximum) or frequencies and percentages - as appropriate for the type of data - will be summarized by each time point; mixed models will be used to analyze the longitudinal measurements, allowing to take into account the within subject correlation and to straightforwardly analyze unbalanced data that may arise in the study.

Interim Analysis We plan to performed an interim cross-sectional analysis at the end of patient enrollment in order to describe the study population at baseline, according to the primary and secondary endpoints.

Sample size

We plan to include all the RSTS patients consecutively operated on for primary retroperitoneal sarcoma from first accrual on for the next 24 months (about 60 patients estimated.

A sample size of 60 patients allows the estimation of a two-sided 95,0% confidence interval for the paired difference between baseline and post treatment scores with a precision (half CI width) of 0.25 times the standard deviation of the difference.

02

Conditions studied

  • Sarcoma, Soft Tissue
  • Retroperitoneal Neoplasms
  • Surgery
  • Quality of Life
  • Morbidity

Browse trials for

Keywords

  • retroperitoneal sarcoma
  • quality of life
  • morbidity
  • surgery
03

In context

Sarcoma

1,607 studies on the registry are indexed under Sarcoma; 366 are open to participants now.

This study's enrollment of 60 is below the median of 120 across 218 observational studies indexed under Sarcoma.

Browse Sarcoma studies →

Lead sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is the lead sponsor of 172 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary retroperitoneal sarcoma candidated to multivisceral resection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients affected by primary retroperitoneal sarcoma and candidated to complete surgery (multivisceral resection)

Exclusion criteria

Exclusion Criteria:

  • Recurrent Disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Global Health Status

    Change between baseline and 4 and 12 months scores of the "global health status / QoL" scale in patients primarily treated for localized RSTS, as determined in QLQ-C30 version 3.0.

    Time frame: 4 and 12 months postoperatively

Secondary outcomes

  1. Renal failure

    Evaluate the long term morbidity of aggressive surgical approach to RSTS in terms of renal failure.

    Time frame: 12 months postoperatively

  2. DN4 questionnaire for neuropathic pain

    Change between baseline and 4 and 12 months scores

    Time frame: 4 and 12 months postoperatively

  3. LEFS questionnaire for lower limb function

    Change between baseline and 4 and 12 months scores

    Time frame: 4 and 12 months postoperatively

  4. BPI questionnaire for chronic pain

    Change between baseline and 4 and 12 months scores

    Time frame: 4 and 12 months postoperatively

  5. QLC-C30, Functional Scales

    Change between baseline and 4 and 12 months scores

    Time frame: 4 and 12 months postoperatively

  6. QLC-C29

    Change between baseline and 4 and 12 months scores

    Time frame: 4 and 12 months postoperatively

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Fiore M, Brunelli C, Miceli R, Manara M, Lenna S, Rampello NN, Callegaro D, Colombo C, Radaelli S, Pasquali S, Caraceni AT, Gronchi A. A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery. Ann Surg Oncol. 2021 Jul;28(7):3904-3916. doi: 10.1245/s10434-020-09307-7. Epub 2020 Nov 11. PubMed 33175262 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jan 2016 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2016
First posted
Mar 29, 2018
Start
Jan 2014
Primary completionActual
Jan 2016
CompletionEst.
Jan 2021
Last update
Aug 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03480399
Responsible party
Marco Fiore (Attending Surgeon, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano) — Principal investigator
First posted
Mar 29, 2018
Start date
Jan 2014
Primary completion
Jan 2016
Completion
Jan 2021 (estimated)
Last update
Aug 7, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion